Secretome Proteomic Approaches for Biomarker Discovery: An Update on Colorectal Cancer

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2020 Sep 4

PMID 32878319

Citations 4

Authors

Armando Cevenini

Stefania Orru

Esther Imperlini

Affiliations

Soon will be listed here.

Abstract

Searching for new cancer-related biomarkers is a key priority for the early detection of solid tumors, such as colorectal cancer (CRC), in clinically relevant biological fluids. The cell line and/or tumor tissue secretome represents a valuable resource for discovering novel protein markers secreted by cancer cells. The advantage of a secretome analysis is the reduction of the large dynamic range characterizing human plasma/serum, and the simultaneous enrichment of low abundance cancer-secreted proteins, thereby overcoming the technical limitations underlying the direct search in blood samples. In this review, we provided a comprehensive overview of recent studies on the CRC secretome for biomarker discovery, focusing both on methodological and technical aspects of secretome proteomic approaches and on biomarker-independent validation in CRC patient samples (blood and tissues). Secretome proteomics are mainly based on LC-MS/MS analyses for which secretome samples are either in-gel or in-solution trypsin-digested. Adequate numbers of biological and technical replicates are required to ensure high reproducibility and robustness of the secretome studies. Moreover, another major challenge is the accuracy of proteomic quantitative analysis performed by label-free or labeling methods. The analysis of differentially expressed proteins in the CRC secretome by using bioinformatic tools allowed the identification of potential biomarkers for early CRC detection. In this scenario, this review may help to follow-up the recent secretome studies in order to select promising circulating biomarkers to be validated in larger screenings, thereby contributing toward a complete translation in clinical practice.

Citing Articles

High-Throughput Mass Spectrometry Analysis of -Glycans and Protein Markers after Knockdown in the Syngeneic SW480/SW620 Colorectal Cancer Cell Model.

Lopez-Cortes R, Muinelo-Romay L, Fernandez-Briera A, Gil Martin E J Proteome Res. 2024; 23(4):1379-1398.

PMID: 38507902 PMC: 11002942. DOI: 10.1021/acs.jproteome.3c00833.

A Subset of Colon Cancer Cell Lines Displays a Cytokine Profile Linked to Angiogenesis, EMT and Invasion Which Is Modulated by the Culture Conditions In Vitro.

Bersano J, Lashuk K, Edinger A, Schueler J Cells. 2023; 12(21).

PMID: 37947617 PMC: 10648033. DOI: 10.3390/cells12212539.

Cancer secretome: finding out hidden messages in extracellular secretions.

Padgaonkar M, Shendre S, Chatterjee P, Banerjee S Clin Transl Oncol. 2022; 25(5):1145-1155.

PMID: 36525229 DOI: 10.1007/s12094-022-03027-y.

Differential plasma proteomes of the patients with and cholangiocarcinoma identify a polymeric immunoglobulin receptor as a potential biomarker.

Prasopdee S, Yingchutrakul Y, Krobthong S, Pholhelm M, Wongtrakoongate P, Butthongkomvong K Heliyon. 2022; 8(10):e10965.

PMID: 36247154 PMC: 9562451. DOI: 10.1016/j.heliyon.2022.e10965.

References

Ferlizza E, Solmi R, Miglio R, Nardi E, Mattei G, Sgarzi M . Colorectal cancer screening: Assessment of , , and as blood markers in faecal immunochemical test negative subjects. J Adv Res. 2020; 24:99-107. PMC: 7113625. DOI: 10.1016/j.jare.2020.03.001. View

Pavlou M, Diamandis E . The cancer cell secretome: a good source for discovering biomarkers?. J Proteomics. 2010; 73(10):1896-906. DOI: 10.1016/j.jprot.2010.04.003. View

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

Austin H, Henley S, King J, Richardson L, Eheman C . Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening. Cancer Causes Control. 2013; 25(2):191-201. PMC: 4394895. DOI: 10.1007/s10552-013-0321-y. View

Sachdev D, Yee D . The IGF system and breast cancer. Endocr Relat Cancer. 2001; 8(3):197-209. DOI: 10.1677/erc.0.0080197. View

Bozzi F, Mogavero A, Varinelli L, Belfiore A, Manenti G, Caccia C . MIF/CD74 axis is a target for novel therapies in colon carcinomatosis. J Exp Clin Cancer Res. 2017; 36(1):16. PMC: 5260021. DOI: 10.1186/s13046-016-0475-z. View

Thomas P, Kejariwal A, Campbell M, Mi H, Diemer K, Guo N . PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. 2003; 31(1):334-41. PMC: 165562. DOI: 10.1093/nar/gkg115. View

Pathan M, Fonseka P, Chitti S, Kang T, Sanwlani R, Van Deun J . Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2018; 47(D1):D516-D519. PMC: 6323905. DOI: 10.1093/nar/gky1029. View

Morandi A, Giannoni E, Chiarugi P . Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk. Trends Cancer. 2017; 2(12):736-746. DOI: 10.1016/j.trecan.2016.11.001. View

10.

Papaleo E, Gromova I, Gromov P . Gaining insights into cancer biology through exploration of the cancer secretome using proteomic and bioinformatic tools. Expert Rev Proteomics. 2017; 14(11):1021-1035. DOI: 10.1080/14789450.2017.1387053. View

11.

Siegel R, Fedewa S, Anderson W, Miller K, Ma J, Rosenberg P . Colorectal Cancer Incidence Patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017; 109(8). PMC: 6059239. DOI: 10.1093/jnci/djw322. View

12.

de Bock M, de Seny D, Meuwis M, Chapelle J, Louis E, Malaise M . Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol. 2009; 2010:906082. PMC: 2793423. DOI: 10.1155/2010/906082. View

13.

Ji H, Greening D, Barnes T, Lim J, Tauro B, Rai A . Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013; 13(10-11):1672-86. DOI: 10.1002/pmic.201200562. View

14.

Swiderska M, Choromanska B, Dabrowska E, Konarzewska-Duchnowska E, Choromanska K, Szczurko G . The diagnostics of colorectal cancer. Contemp Oncol (Pozn). 2014; 18(1):1-6. PMC: 4037991. DOI: 10.5114/wo.2013.39995. View

15.

Severino V, Farina A, Chambery A . Analysis of secreted proteins. Methods Mol Biol. 2013; 1002:37-60. DOI: 10.1007/978-1-62703-360-2_4. View

16.

Toby T, Fornelli L, Srzentic K, DeHart C, Levitsky J, Friedewald J . A comprehensive pipeline for translational top-down proteomics from a single blood draw. Nat Protoc. 2018; 14(1):119-152. PMC: 6439476. DOI: 10.1038/s41596-018-0085-7. View

17.

Schaaij-Visser T, de Wit M, Lam S, Jimenez C . The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta. 2013; 1834(11):2242-58. DOI: 10.1016/j.bbapap.2013.01.029. View

18.

Link-Lenczowski P, Jastrzebska M, Chwalenia K, Pierzchalska M, Leja-Szpak A, Bonior J . A switch of N-glycosylation of proteome and secretome during differentiation of intestinal epithelial cells. Biochim Biophys Acta Mol Cell Res. 2019; 1866(12):118555. DOI: 10.1016/j.bbamcr.2019.118555. View

19.

Harsha H, Molina H, Pandey A . Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat Protoc. 2008; 3(3):505-16. DOI: 10.1038/nprot.2008.2. View

20.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View